ArticleJournal of Korean medical science2026
Predictors of Treatment Outcomes in Pediatric Graves' Disease.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraves' disease (GD), the most common cause of hyperthyroidism in children, is primarily treated with antithyroid drugs (ATDs). The aim of this study was to evaluate factors that could predict remission, relapse, and the need for persistent high doses of methimazole (MMI) in pediatric GD.
methodsThis was a retrospective study of medical records that included GD diagnosed before 19 years of age from January 2004 to December 2023. Remission was defined as maintaining the euthyroid state for more than 6 months after stopping ATDs. The high-dose group was defined as those receiving MMI doses of more than 5 mg/day at last follow-up, regardless of euthyroid status.
resultsOf the 113 patients (95 girls and 18 boys), 47 (41.6%) achieved remission at a mean of 37.17 ± 29.01 months after treatment. Compared to the non-remission group, the remission group showed significant differences in T3, fT4 and thyroid-stimulating hormone-binding inhibitor immunoglobulin (TBII) at diagnosis (330.92 ± 177.72 vs. 413.75 ± 179.09 ng/dL,
conclusionThyroid hormone and TBII levels at diagnosis, time to thyroid hormone and TBII normalization, and the TBII ratio after ATD treatment can be used to predict remission, relapse, and the persistent need for high-dose MMI in pediatric GD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.